Excoiting, page-5

Comrades,
The thread heading says it all, so much to look forward to, can´t wait to see what is happening with Artimist.

ARTIMIST. SUDA has received positive responses from the reviewers of the Marketing Authorisation Application at the TGA. The application was accepted for review in April 2017. Subject to some outstanding questions, which SUDA and its contractors are addressing,
MARKETING APPROVAL IS ANTICIPATED BY JUNE 2019.

http://sudapharma.com/attachments/article/35/946%20Annual%20Report%2028%20sept%202018.pdf

One would have to assume SUD has huge potential to rocket post TGA! Surely there has to be a buyer around based on the positive results contained in these two reports! Have a read.

Prof. Stephen Rulisa's presentation from 2014 (pg.453) and...article by Prof Tim Davis,(2015) both of whom are part of Suda's Clinical Advisory Board

https://www.astmh.org/ASTMH/media/Documents/ASTMH2014AbstractBookFINAL.pdf

https://aac.asm.org/content/aac/early/2015/03/17/AAC.05013-14.full.pdf